上海岸迈生物科技有限公司

上海岸迈生物科技有限公司是位于上海浦东新区张江高科技园区的一家新兴的创新型国际化生物技术企业，专注于利用自主知识产权的双特异性抗体技术平台（FIT-Ig®）进行创新生物药的研究和开发。FIT-Ig®技术是一项新型的双特异性抗体的技术平台，该技术平台能够通过简单的分子生物学手段将两个抗体串联在一起形成双抗，该双抗同时具备了两个原始抗体的功能，拥有双重活性和产业化优势。基于FIT-Ig®平台技术，岸迈生物目前拥有十几个自主开发的 First-in-class 生物大分子新药研发项目，专注于恶性肿瘤靶向治疗，肿瘤免疫，T细胞导向治疗等领域。其中有三个品种处于临床前开发阶段，预计2018 年在国内外进行第一个产品的临床研究。FIT-Ig®技术同时也吸引了国内外多个主流生物医药企业的关注，目前已经和包括信达生物、英国Kymab公司等在内的多家企业达成了技术与产品的合作，岸迈将通过技术授权、合作开发、共享收益等多种形式实现平台战略发展，为国内药企开发双抗药物起到了引领示范和带头作用。2017初，岸迈生物成功完成A轮2500万美元融资，由元禾原点领投，德诚资本、本草资本、趋势资本跟投。2017年9月，岸迈生物荣获2017年中国创新创业大赛（生物医药行业初创组）全国总决赛冠军。 公司网页：www.epimab.com 简历投递：hr@epimab.com About EpimAb Biotherapeutic EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own First-in-class bispecific antibody therapeutics focused on immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. In April 2017 EpimAb completed a $25 million Series A financing round, led by Oriza Seed Capital and included investments from Decheng Capital, 3E Bioventures Capital and the Trend Investment Group. In September 2017, EpimAb won first prize in China Innovation and Entrepreneurship Competition, the most prestigious award in China promoting innovation across different industries. Web:www.epimab.com Email:hr@epimab.com